Swiss Pharmaceutical Company Reveals Promising Preclinical Results For Parkinson's Disease

NLS Pharmaceutics Ltd. (NASDAQ: NLSP)(NASDAQ: NLSPW), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for rare and complex central nervous system disorders, has announced preclinical results from multiple in vitro studies targeting the alpha-synuclein protein (α-synuclein), particularly the A53T mutation. These findings indicate that certain compounds have the potential to provide new treatment avenues for Parkinson's Disease (PD). These compounds are being evaluated under an existing license agreement with Aexon Labs, Inc. (Aexon Labs or AEX). $NLS Pharmaceutics(NLSP.US)$